B. CETIN Et Al. , "Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).," Journal of chemotherapy (Florence, Italy) , vol.26, pp.300-5, 2014
CETIN, B. Et Al. 2014. Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).. Journal of chemotherapy (Florence, Italy) , vol.26 , 300-5.
CETIN, B., BENEKLI, M., TURKER, I., Koral, L., ULAS, A., DANE, F., ... OKSUZOGLU, B.(2014). Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).. Journal of chemotherapy (Florence, Italy) , vol.26, 300-5.
CETIN, BARIŞ Et Al. "Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).," Journal of chemotherapy (Florence, Italy) , vol.26, 300-5, 2014
CETIN, BARIŞ Et Al. "Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).." Journal of chemotherapy (Florence, Italy) , vol.26, pp.300-5, 2014
CETIN, B. Et Al. (2014) . "Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).." Journal of chemotherapy (Florence, Italy) , vol.26, pp.300-5.
@article{article, author={BARIŞ CETIN Et Al. }, title={Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).}, journal={Journal of chemotherapy (Florence, Italy)}, year=2014, pages={300-5} }